Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646175 | 0.88 | TP53 (0.46) | ALDH1A1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL644994 | 0.72 | CA12 (0.50) | ALDH1A1CYP3A4CYP2D6CA12CA7 | |
| SCHEMBL6264679 | 0.70 | CA1 (0.48) | ALDH1A1TP53TDP1CA1 | |
| SCHEMBL28013475 | 0.67 | PTGS1 (0.54) | ALDH1A1TSHRTDP1 | |
| SCHEMBL11836972 | 0.66 | MCL1 (0.54) | ALDH1A1TP53TDP1CA1CHRM3 | |
| SCHEMBL14292324 | 0.66 | MAPT (0.68) | ALDH1A1TP53CA1 | |
| SCHEMBL28789732 | 0.66 | MAPT (0.68) | ALDH1A1TP53CA1 | |
| SCHEMBL28012787 | 0.66 | PTGS1 (0.44) | — | |
| SCHEMBL10493317 | 0.65 | CA1 (0.55) | ALDH1A1TP53CA1 | |
| SCHEMBL7398925 | 0.64 | SLC15A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101326151-B | Improved method for the production of ramipril | SANOFI AVENTIS DEUTSCHLAND | 2015-01-07 | — | — | CN | disclosed |
| US-8119375-B2 | Method for the production of ramipril | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090017509-A1 | METHOD FOR THE PRODUCTION OF RAMIPRIL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| CN-101326151-A | Improved method for the production of ramipril | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017509-A1 | METHOD FOR THE PRODUCTION OF RAMIPRIL | REN, PDE8B, PDE3A | ALDH1A1 460/4885TP53 4824/4885CYP1A2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.